The US Food and Drug Administration (FDA) has approved sarecycline (Seysara, Almirall) for patients aged 9 years and older with inflammatory lesions associated with non-nodular moderate to severe acne vulgaris. Sarecycline is a new first-in-class tetracycline-derived oral antibiotic and the first one specifically designed for dermatologic use in 40 years, according to a company news release.
“We are proud to have obtained the FDA’s approval for Seysara, which will bring a new option for the many patients with unmet medical needs,” Peter Guenter, chief executive officer, Almirall, said in the news release.
Sarecycline is a once-daily oral tablet with anti-inflammatory properties that can be taken with or without food.
Read the article click here
Back to Hot off the Press Page